Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma

Oishi, Seiichi; Satô, Tatsuo

doi:10.1002/1097-0142(19880315)61:6<1167::aid-cncr2820610618>3.0.co;2-u

Cited by 35 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a widely used immunohistochemical and serum marker for neuroendocrine tissues and is especially known as a marker for small cell lung carcinoma (26). Our data confirm the frequent elevation of its serum concentrations in patients with several neuroendocrine tumors (27)(28)(29). The highest levels were encountered in small cell lung carcinoma and in the rare cases of Merkel cell tumors.…”

Section: Discussionsupporting

confidence: 86%

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein Hormones

Nobels¹

1997

Journal of Clinical Endocrinology & Metabolism

199

202

View full text Add to dashboard Cite

Chromogranin A (CgA) is gaining acceptance as a serum marker of neuroendocrine tumors. Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect small tumors, and its clinical value, compared with other neuroendocrine markers, have not clearly been defined, however. The objectives of this study were to evaluate the clinical usefulness of CgA as neuroendocrine serum marker. Serum levels of CgA, neuron-specific enolase (NSE), and the ␣-subunit of glycoprotein hormones (␣-SU) were determined in 211 patients with neuroendocrine tumors and 180 control subjects with nonendocrine tumors. The concentrations of CgA, NSE, and ␣-SU were elevated in 50%, 43%, and 24% of patients with neuroendocrine tumors, respectively. Serum CgA was most frequently increased in subjects with gastrinomas (100%), pheochromocytomas (89%), carcinoid tumors (80%), nonfunctioning tumors of the endocrine pancreas (69%), and medullary thyroid carcinomas (50%). The highest levels were observed in subjects with carcinoid tumors.

show abstract

Section: Discussionsupporting

confidence: 86%

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein Hormones

Nobels¹

1997

Journal of Clinical Endocrinology & Metabolism

199

202

View full text Add to dashboard Cite

show abstract

“…Secretogranin II and prohormone convertases 1 and 2 were found to be overexpressed in benign when compared with malignant tumours (Guillemot et al 2006). Neuron-specific enolase has also been advocated as a screening marker since it can be significantly elevated in patients with malignant phaeochromocytomas (Oishi & Sato 1988). Of the several other peptides that can be produced from chromaffin-cell tumours, adrenocorticotrophin over-expression has been related to malignancy (Moreno et al 1999).…”

Section: Biochemical Diagnosis Of Malignant Chromaffin-cell Tumoursmentioning

confidence: 99%

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Chrisoulidou

Kaltsas²,

Ilias³

et al. 2007

Endocr Relat Cancer

296

219

View full text Add to dashboard Cite

Malignant phaeochromocytomas are rare tumours accounting for w10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations. Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour. Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours. Although a number of recently introduced molecular markers have been explored, their clinical significance remains to be elucidated from further studies. Several imaging modalities have been utilised for the diagnosis and staging of these tumours. Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, 18 F-fluorodopamine and 18 F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies. The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion. Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using 131 I-MIBG; however, this is very rarely curative. Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect. The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving. Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.

show abstract

“…In accordance, chromogranin A has been used to monitor patients during chemotherapy of malignant PCCs [55]. Some investigators have reported a high serum concentration of neuron-specific enolase (NSE) [56].…”

Section: Unspecific Biomarkersmentioning

confidence: 99%

Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

Gimm

DeMicco

Perren

et al. 2011

Langenbecks Arch Surg

View full text Add to dashboard Cite

Due to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.

show abstract

Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma

Cited by 35 publications

References 16 publications

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein Hormones

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein Hormones

The diagnosis and management of malignant phaeochromocytoma and paraganglioma

Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

Contact Info

Product

Resources

About